The 4th Annual Biologics CDMO Asia 2025
Bioconjugation Insights 2025; 1(3), 79–80
DOI: 10.18609/bci.2025.017
As part of our ongoing coverage of key gatherings in the bioconjugation space, Bioconjugation Insights presents an event preview of the 4th Annual Biologics CDMO Asia 2025. The event emerges as the definitive platform to explore contract development and manufacturing innovation across the Asia-Pacific region, uniting C-level executives, manufacturing leaders and regulatory stakeholders to foster partnerships and address challenges in scalability, compliance, and technological integration. From smart tech transfers to CGT manufacturing, this two-day summit delivers the strategies needed to stay competitive in a fast-evolving biomanufacturing ecosystem.
.webp) |
Event highlights
The 4th Annual Biologics CDMO Asia 2025 features a dynamic agenda focused on aligning biomanufacturing strategies with Asia’s accelerating demand for biologics. The event opens with strategic insights from Christopher Pawlak, Bayer, Daniel Hurni, Bristol Myers Squibb, and Hu Jun, WuXi XDC in a high-level panel on global CDMO partnerships, emphasizing how multinational companies are aligning capabilities with the region s biomanufacturing boom. Further to the panel, keynote speaker Christopher Pawlak presents a compelling roadmap for strategic supplier management, integrating performance metrics, cultural alignment, and digital tools to futureproof external manufacturing operations. Day 1 sessions will explore the full CDMO lifecycle, with insights on global network design and supplier positioning. Jennifer Kuan, Bora Biologics, will outline how regional site specialization supports faster, more flexible tech transfers from early-stage to commercial production.
In the digital sphere, Nora Pataut, GSK, reveals how standardized digital frameworks are revolutionizing CMC tech transfers, and Kamyar Sadri, Novo Nordisk, discusses AI s transformative potential in CDMO ecosystems. Zach Pang, ASTAR Bioprocessing Technology Institute (BTI), offers a deep dive into computational workflows for optimizing culture media, especially for new modalities.
Day 2 kicks off with Bi Xuezhi, ASTAR Bioprocessing, examining mass spectrometry s growing role in real-time biologics quality control. Jimmy Chang, TaiMed Biologics, recounts lessons from developing and commercializing the world s first FDA-approved HIV monoclonal antibody an inspiring look at R&D-to-commercial translation through CDMO partnerships.
The regulatory spotlight features a robust panel discussion with experts Sudeep Srivastava, TechInvention Lifecare, Jimmy Chang, TaiMed,, Rakesh Kumar Sinha, Biological E. Limited, and Akhil Prakash Chincholikar, Naprod Life Sciences, tackling APAC-specific compliance challenges. Follow-up sessions examine how CDMOs are adapting to the evolving landscape through precision medicine, biologics, and strategic approaches like smart manufacturing and total quality management to enhance regulatory compliance, cost efficiency and capacity realisation.
Asia’s innovation potential is further spotlighted through case studies on scaling CDMO capacity, technology adoption, and strategic biotech partnerships. The agenda concludes with a strong focus on next-generation modalities: Warren Chan, WTU, explores mRNA, cell, and gene therapies, while Andy Tan, A*STAR showcase case studies on cell-based immunotherapies.
Whether you’re optimizing tech transfer, expanding capacity, or adopting AI for regulatory efficiency, the 4th Annual Biologics CDMO Asia 2025 is your gateway to scalable biomanufacturing, strategic CDMO partnerships, next-generation therapies, and Asia-Pacifics booming biologics ecosystem uniting innovation, compliance, and collaboration under one roof.
As a reader of Bioconjugation Insights, you’re entitled to a 15% discount on delegate tickets—just reach out to kingsley.chukwura@imapac.com! You can find out more about the event here.
Additionally, to find out what other bioconjugate events are upcoming, you can find our online Events Calendar here.